Congratulations to Dr. Laura Sly and her team! They are accelerating the development of innovative new drugs for patients with inflammatory bowel disease (IBD) thanks to the support of a new grant from Crohn’s and Colitis Canada.
The goal of Dr. Sly’s project is to develop a drug delivery system that allows for lower drug dosages, which will lessen side effects and make more drug options available. Her research is developing a gut drug delivery mechanism that coats drugs in a sugar cage that allows it to be delivered precisely to areas of gut inflammation.
“Long term, we hope that this technology can be applied to other IBD drugs so that they can be used safely and earlier in IBD treatment,” Dr. Sly said. “These are essential next steps in translating our glycocage technology to real world solutions for people with IBD. We’re really excited about the potential of this technology to improve the lives of people living with IBD.”
More:
https://crohnsandcolitis.ca/Research/Funded-research/Discovering-Novel-Treatments